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3Merck’s Adenovirus-Based Vaccines
• Replication-incompetent adenovirus 
– E1 deficient
– Propagated in E1-complementing cell line 
(PER.C6™)
• For HIV Vaccine, incorporates 
transgenes for HIV-1 gag, pol, and nef
– Could incorporate any gene of interest
• Monovalent or multivalent
– Single construct or multiple constructs
– Mono-gene or multi-gene





4How Was it Designed to Work?
Presented by MHC to T-Cells Immune Response
•No functionality
•Polypeptide sequence only is 
critical
5Hope and Disappointment in HIV 
Vaccine Development at Merck
• Phase I studies showed strong immune response in 
recipients
– Animal studies had shown reduction in viral load
• Phase II studies, initiated in 2004, were designed to test 
if the immune response elicited was sufficient for efficacy
• Disappointingly, the results from Phase II (Sept. 2007) 
suggested that the measured ELISPOT was not 
indicative of efficacy
6Why Discuss it Further?
• Hopefully others can learn from this, and speed 
development of other HIV vaccines
– "If I have seen further, it is by standing on the shoulders of giants.”  
--Sir Isaac Newton, 1675
– Other Adenovirus-based vaccines are being developed
• Merck was preparing for Phase III and potential 
launch
– This is a good case study for how to move toward 
“well-characterized” live virus vaccines
















*Raw material testing is also important at each stage
8What Should This Talk Convey?
1. The extensive analytical complexity of 
this program as a whole
2. How we have been able to get our arms 
around this complexity
Attention to detailed science makes a 
difference in true understanding and control
9Unique Challenges in Adenovirus-






Efficacy?  Productivity in manufacturing.
Antigen Expressing Particles 













Need to assess these attributes for all sub-populations of viral particles
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Breadth and Depth
• Each of the subsequent slides could 
have 20 slides describing the story 
behind it
• The goal of this talk is not to “wow” 
you with detailed data, but to 
illustrate the variation and 
complexity (and sheer numbers) of 




















Sources: Huyghe, 1995; Misc Patent 
Applications (Introgen, Aventis, Canji, Schering)
The end product is a 




•Unexpected bands observed in all digests suggesting possible deletions
•Led to cloning of fragments, sequence identification, ultimately 
potentially to re-design of original plasmid construct
Challenges With Identity/Purity
A seemingly simple 
observation kicked 




to a critical 
conclusion.
C. Wang et al
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Purity:  Unique Challenges with 
PER.C6 Cells 
Neuronal cell type from human fetus previously 
unlicensed for use in vaccines 
Prior cell expansion with bovine serum 
Transformed and non-adherent phenotype 
Recombinant E1-encoding expression system
Duncan et al
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Purity:  Extensive Testing to Detect 
Potentially Contaminating Viruses
• Tests in cell lines    








Purity:  Protein Clearance by SDS-PAGE



























































Konz, Soohoo, et al
Tracking clearance through the process gave good 
confidence in the end product purity.
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Purity:  Host Impurity Clearance
•Approximately 7 log clearance in host cell DNA after purification
•Final product is largely free of host contaminants
Konz, Goerke, DiStefano, Pitts, and Sagar
DNAProtein
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Purity:  Quantification of Empty Capsids
Full Empty
Sweeney et al (in prep)

















•Three methods developed for this 
critical parameter.  
•Orthogonal assays led to increased 




Assays for Strength (i.e., Dose)




• Key assay attributes
– Accurate, precise, specific, and 
reproducible
– Flexible for multiple constructs
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Strength:  Aggregation Issues
Relatively straight-forward 
measures of aggregation 

































































37°C, T = 11 days




Wang F., Puddy AC,  Mathis BC, et al. Vaccine.  23, 4500-4508 (2005)
Gained precision and specificity in an infectivity assay, but 












































1 10 100 1000 10000
Parallel-line analysis
Plant A549 cells Infect cells
48 hr 48 hr
Cell lysis
Advantages:
• Likely the most relevant measure of vaccine activity; Specific; Precise
Disadvantages:
• Choosing appropriate antibodies was complex and time-consuming
• Consistency and availability of reagents moving forward is challenging
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¾ Infectivity and antigen expression assay results were similar
¾ Variability was slightly lower in the IVAE 
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Analytical and Clinical Data Relationship
•In both the clinical and IVAE data, trivalent vaccine generated slightly 
stronger responses (not statistically significant clinically)
•Only true for “high Ad5” clinical population
•Suggested IVAE might be the more clinically relevant assay
•IVAE has operational disadvantages








































Clinical Data In Vitro Expression Data
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Investment in Assay Development




Genome Quantitation Assay (GQA)
Reverse-Phase HPLC Assay
CsCl Gradient Analysis (% full)




Q-PCR Based Potency Assay (QPA)
Antigen Expressing Particles 
Silver stain/Western blot









•Manufacture in a 
permissive cell-line












Stability•Never-before used in 
human trials












There are analytical challenges at each stage
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Are We There Yet?
• Significant understanding of the 
cellular and molecular biology, 
biophysics, and physical chemistry 
of the vaccine has been attained
• Most assays are suitable for 
“platform” testing
• The missing link is clinical efficacy
































Many, many others within and outside of Merck
Robyn Reinmiller
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“We try never to forget that medicine 
is for the people--it is not for the 
profits.  The profits follow, and if we 
have remembered that, they have 
never failed to appear.”
--George W. Merck, December, 1950
